Introduction

Bone loss/resorption or osteoporosis is a disease that is accelerated with aging and age-associated chronic diseases such as cancer. Bone loss has been linked with human multiple myeloma, breast cancer, and prostate cancer and is usually treated with bisphosphonates, and recently approved denosumab, an antibody against receptor activator of NF-κB ligand (RANKL). Because of the numerous side effects of the currently available drugs, the search continues for safe and effective therapies for bone loss. RANKL, a member of the TNF superfamily, has emerged as a major mediator of bone loss via activation of osteoclastogenesis. We have identified cardamonin, a chalcone isolated from Alpinia katsumadai Hayata that can affect osteoclastogenesis through modulation of RANKL. We found that treatment of monocytes with cardamonin suppressed RANKL-induced NF-κB activation and this suppression correlated with inhibition of IκBα kinase and of phosphorylation and degradation of IκBα, an inhibitor of NF-κB. Furthermore, cardamonin also downregulated RANKL-induced phosphorylation of MAPK including ERK and p38 MAPK. Cardamonin suppressed the RANKL-induced differentiation of monocytes to osteoclasts in a dose-dependent and time-dependent manner. We also found that an inhibitor of NF-κB essential modulator (NEMO) blocked RANKL-induced osteoclastogenesis, indicating a direct link with NF-κB. Finally, osteoclastogenesis induced by human breast cancer cells or human multiple myeloma cells were completely suppressed by cardamonin. Collectively, our results indicate that cardamonin suppresses osteoclastogenesis induced by RANKL and tumor cells by suppressing activation of the NF-κB and MAPK pathway.

Abstract

Bone loss/resorption or osteoporosis is a disease that is accelerated with aging and age-associated chronic diseases such as cancer. Bone loss has been linked with human multiple myeloma, breast cancer, and prostate cancer and is usually treated with bisphosphonates, and recently approved denosumab, an antibody against receptor activator of NF-κB ligand (RANKL). Because of the numerous side effects of the currently available drugs, the search continues for safe and effective therapies for bone loss. RANKL, a member of the TNF superfamily, has emerged as a major mediator of bone loss via activation of osteoclastogenesis. We have identified cardamonin, a chalcone isolated from Alpinia katsumadai Hayata that can affect osteoclastogenesis through modulation of RANKL. We found that treatment of monocytes with cardamonin suppressed RANKL-induced NF-κB activation and this suppression correlated with inhibition of IκBα kinase and of phosphorylation and degradation of IκBα, an inhibitor of NF-κB. Furthermore, cardamonin also downregulated RANKL-induced phosphorylation of MAPK including ERK and p38 MAPK. Cardamonin suppressed the RANKL-induced differentiation of monocytes to osteoclasts in a dose-dependent and time-dependent manner. We also found that an inhibitor of NF-κB essential modulator (NEMO) blocked RANKL-induced osteoclastogenesis, indicating a direct link with NF-κB. Finally, osteoclastogenesis induced by human breast cancer cells or human multiple myeloma cells were completely suppressed by cardamonin. Collectively, our results indicate that cardamonin suppresses osteoclastogenesis induced by RANKL and tumor cells by suppressing activation of the NF-κB and MAPK pathway.

Citation: Sung B, Prasad S, Yadav VR, Gupta SC, Reuter S, et al. (2013) RANKL Signaling and Osteoclastogenesis Is Negatively Regulated by Cardamonin. PLoS ONE 8(5): e64118. doi:10.1371/journal.pone.0064118

Editor: Anindita Das, Virginia Commonwealth University, United States of America

Received February 5, 2013; Accepted April 9, 2013; Published May 17, 2013

Copyright: © 2013 Sung et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: These authors have no support or funding to report.

Competing Interests: Dr. Norio Yamamoto is employed by House Wellness Foods Corporation. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: aggarwal@mdanderson.org

These authors contributed equally to this work.
suppress RANKL signaling and have potential for inhibition of osteoclastogenesis and bone metastasis. Previous studies have demonstrated that cardamonin ((2E)-1-(2,4-Dihydroxy-6-methoxy-phenyl)-3-phenyl-2-propen-1-one)), a chalcone isolated from grass cardamom (Alpinia katsumadai Hayata) and black cardamom (Amomum subulatum) can suppress NF-κB activation induced by a variety of agents [11,12]. Because both RANKL and NF-κB pathway have been closely linked with osteoclastogenesis, we decided to investigate the effect of this chalcone on RANKL-induced NF-κB activation pathway and osteoclastogenesis. We found that cardamonin can suppress RANKL-induced NF-κB activation through inhibition of IKK and inhibits osteoclastogenesis induced by RANKL and by breast cancer and multiple myeloma cells.

Materials and Methods

Reagents

Cardamonin (synthesized and kindly provided by Dr. Norio Yamamoto) was prepared as 20 mM solution in dimethyl sulfoxide and then further diluted in cell culture medium. Dulbecco modified essential medium (DMEM/F12), RPMI 1640, DMEM, fetal bovine serum, 0.4% trypsin blue vital stain, and antibiotic-antimycotic mixture were obtained from Mediatech, Inc. (Manassas, VA). Recombinant RANKL protein was kindly provided by Dr. Bryant Darnay of The University of Texas MD Anderson Cancer Center (Houston, TX). Antibodies against RANKL, IKKα, IKKβ and IkBα were purchased from Imgenex (San Diego, CA), while cell-permeable NF-κB essential modulator (NEMO; also called IKKε)–binding domain peptide (NBP) were kind gifts from Imgenex. Antibodies against phospho-IκBα (Ser32/36), and phospho-IκBβ (Thr202/Tyr204), ERK2, phospho-p38 (Tyr180/182) and p38 (Ser176)/IKKα (Ser177) were purchased from Cell Signaling Technology (Danvers, MA). Antibodies against c-Src, NFAFc, MMP-9, phospho-ERK1/2 (Thr202/Tyr204), ERK2, phospho-p38 (Tyr180/182) and p38 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Goat anti-rabbit and goat anti-mouse horseradish peroxidase conjugates were purchased from Bio-Rad (Hercules, CA). β-actin antibody and leukocyte acid phosphatase kit (387-A) for tartrate-resistant acid phosphatase (TRAP) staining were purchased from Sigma-Aldrich (St. Louis, MO). Protein A/G-agarose beads were purchased from Bio-Rad (Hercules, CA). Goat anti-rabbit and goat anti-mouse horseradish peroxidase conjugates were purchased from Bio-Rad (Hercules, CA). β-actin antibody and leukocyte acid phosphatase kit (387-A) for tartrate-resistant acid phosphatase (TRAP) staining were purchased from Sigma-Aldrich (St. Louis, MO). Protein A/G-agarose beads were obtained from Thermo Scientific (Rockford, IL). [γ³²P]ATP was purchased from MP Biomedicals (Solon, OH).

Cell lines

RAW 264.7 (mouse macrophage) cells were kindly provided by Dr. Bryant Darnay. For these studies, we used a single clone (#28) that has been selected after limited dilution. RAW 264.7 cells were cultured in DMEM/F12 supplemented with 10% fetal bovine serum and antibiotics. This cell line is a well-established osteoclastogenic cell system that has been shown to express RANK and to differentiate into functional TRAP-positive osteoclasts when cultured with soluble RANKL [13]. Moreover, RANKL has been shown to activate NF-κB in RAW 264.7 cells [14]. MDA-MB-231 (human breast adenocarcinoma) and U266 (human multiple myeloma) cells were obtained from the American Type Culture Collection (Manassas, VA). MDA-MB-231 cells were cultured in DMEM and U266 cells in RPMI 1640 with 10% fetal bovine serum.

Osteoclast differentiation assay

RAW 264.7 cells were cultured in 24-well plates at a density of 5×10⁴ per well and allowed to adhere overnight. The medium was then replaced, and the cells were treated with 5 nM RANKL for 5 days. All cells were subjected to TRAP staining using the leukocyte acid phosphatase kit. For co-culture experiments with cancer cells, RAW 264.7 cells were seeded at 5×10⁴ per well and allowed to adhere overnight. The following day, U266 or MDA-MB-231 cells, at 1×10⁵ per well, were added to the RAW 264.7 cells, treated with cardamonin, and co-cultured for 5 days before being subjected to TRAP staining.

Electrophoretic mobility shift assay (EMSA) for NF-κB

Nuclear extracts were prepared and EMSA was carried out as described previously [15]. Briefly, equal amount of nuclear extracts from untreated and RANKL-treated cells were incubated with [³²P]-end-labeled 45-mer double-stranded NF-κB oligonucleotide (15 μg protein with 16 fmol DNA) from the HIV long terminal repeat, 5′-TTGTTAACAAGGGACTTTCCGCTGGG-GACCTTCAGGGGGAGCGTG-3′ (underline indicates NF-κB–binding sites), for 30 min at 37°C, and the DNA-protein complex formed was separated from free oligonucleotide on 6.6% native polyacrylamide gels. The dried gels were visualized with a Storm820, and radioactive bands were quantified using a densitometer and Image Quant software (GE Healthcare, Piscataway, NJ).

Western blot analysis

To determine the levels of protein expression in the cytoplasm and nucleus, we prepared extracts and fractionated them by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, the proteins were electrotransferred to nitrocellulose membranes, blotted with relevant antibodies, and detected with a chemiluminescence reagent (GE Healthcare).

IKK assay

To determine the effect of cardamonin on RANKL-induced IKK activation, IKK assay was performed by a method described previously [16]. Briefly, the IKK complex from whole-cell extracts (600 μg protein) was precipitated with antibody against IKKα followed by treatment with protein A/G-agarose beads. After 2 h of incubation, the beads were washed with lysis buffer and assayed in a kinase assay mixture containing 50 mM HEPES (pH 7.4), 20 mM MgCl₂, 2 mM dithiothreitol, 20 μg/ml [γ³²P]ATP, 10 μM unlabeled ATP, and 2 μg of substrate glutathione S-transferase (GST)-IkBα (amino acids 1–54). After incubation at 30°C for 30 min, their action was terminated by boiling with SDS sample buffer for 5 min. Finally, the protein was resolved on 10% SDS-PAGE, the gel was dried, and the radioactive bands were visualized with a Phosphor Imagor. To determine the total amounts of IKKα and IKKβ in each sample, the whole-cell protein was resolved on 10% SDS-PAGE, electrotransferred to nitrocellulose membrane, and blotted with anti-IKKα or anti-IKKβ antibody.

Trypan blue exclusion assay

Cells were harvested by treatment with 0.2% trypsin-EDTA, centrifuged, and suspended in one ml culture medium. Cell suspension was mixed with equal volume of 0.4% isotonic trypan blue solution. Total cell number and fraction of nonviable, dye-accumulating cells were counted after 2 min in hemocytometer under light microscope.

Resorption pit assay

To examine the effect of cardamonin on bone resorption, a pit formation assay was carried out using calcium phosphate apatite-
coated plates essentially following the manufacturer’s protocol (BioCoat Osteologic Bone Cell Culture System; BD Biosciences).

Statistical analysis
All experiments were carried out in triplicates and repeated twice. Data were expressed as mean ± SD and analyzed using Student’s t-test. Statistical significance was considered when a \( P \) value was<0.05.

Results
The aim of this study was to investigate the effect of cardamonin (Fig. 1A) on RANKL signaling and on osteoclastogenesis. Whether cardamonin could modulate osteoclastogenesis induced by tumor cells was another focus of these studies. We used the RAW 264.7 cell (murine macrophage) system because it is a well-established model for osteoclastogenesis and contains no osteoblast/bone marrow stromal cells, thus allowing us to focus on RANKL signaling in pre-osteoclast cells [17].

Cardamonin abrogates RANKL-induced NF-κB activation
To determine the concentration of cardamonin required to suppress RANKL-induced NF-κB activation, cells were pretreated with various concentrations of cardamonin and then exposed to RANKL. The chalcone almost completely suppressed NF-κB activation at 20 μM (Fig. 1B). Treatment of cells with 20 μM of cardamonin for 12 h had no effect on cell viability as determined by the trypan blue exclusion method.

To investigate whether cardamonin modulates RANKL-induced NF-κB activation in RAW 264.7 cells, cells were either pretreated with cardamonin for 12 h or left untreated and then exposed to RANKL for indicated times, nuclear extracts were prepared, and NF-κB activation was assayed by EMSA. As shown in Figure 1C, RANKL activated NF-κB in a time-dependent manner; however, cardamonin completely abrogated RANKL-induced NF-κB activation.

Cardamonin inhibits RANKL-induced IkBα phosphorylation and degradation
Because the proteolytic degradation of IkBα is required for translocation of NF-κB to the nucleus, we next examined whether suppression of NF-κB by cardamonin was due to inhibition of IkBα degradation. First, we examined NF-κB activation in the nucleus by EMSA (Fig. 1C) and IkBα degradation in the cytoplasm by western blot (Fig. 2A), after RANKL stimulation for various times. As shown in Figure 1C, RANKL activated NF-κB as early as within 5 min, and cardamonin completely inhibited this activation. In accordance with EMSA results, RANKL induced IkBα degradation in control cells within 5 min and returned to normal level within 60 min (Fig. 2A). On the other hand, cells pretreated with cardamonin showed no degradation of IkBα.

We next examined whether cardamonin affects the IkBα phosphorylation. Because phosphorylation, ubiquitination and proteasome mediated degradation of IkBα in response to RANKL is a rapid process, we used N-acetyl-leu-leu-norleucinal (ALLN), the proteasome inhibitor that prevents RANKL-induced IkBα degradation (Fig. 2B). When the cells were treated with RANKL alone, the intensity of the phospho-IkBα band was very weak (lane 2 in Fig. 2B). However, when cells were pretreated with ALLN before RANKL, an increase in phospho-IkBα was observed (lane 6 in Fig. 2B). When cells were treated with cardamonin before treatment with ALLN and RANKL, phosphorylation in IkBα was almost completely suppressed (lane 8 in Fig. 2B). Overall, these results suggest that phosphorylation and degradation of IkBα in response to RANKL alone is a rapid process and that cardamonin inhibits RANKL-induced NF-κB activation through suppression of IkBα degradation and phosphorylation.

Cardamonin inhibits RANKL-induced IKK activation
Because cardamonin inhibits the phosphorylation and degradation of IkBα, we next investigated whether cardamonin affects the activity of IKK, which is needed for IkBα phosphorylation. As shown in Fig. 2C, RANKL induced IKK activation and cardamonin inhibited RANKL-induced IKK activation. We next examined whether the loss of IKK activity was due to the alteration of IKK protein expression; the protein levels of IKKα and IKKβ were determined by western blot analysis. Results in Figure 2C clearly show that neither RANKL nor cardamonin altered the expression of IKKα and IKKβ proteins.

Cardamonin inhibits the RANKL-induced phosphorylation of IKK and signaling molecules linked with MAPK pathway
Because RANKL can induce IKK, and signaling molecules associated with MAPK pathway, we examined the effect of cardamonin on these signaling molecules. As shown in Figure 2D, RANKL induced the phosphorylation of IKK, ERK and p38 MAPK in osteoclast precursor RAW264.7 cells. However, pretreatment of cells with cardamonin significantly inhibited the RANKL-induced activation of these kinases.

Cardamonin inhibits RANKL-induced osteoclastogenesis
Whether cardamonin could inhibit RANKL-induced osteoclastogenesis was examined. Osteoclast precursor RAW 264.7 cells were treated with different concentrations of cardamonin in the presence of RANKL and allowed to differentiate into osteoclasts. As shown in Figure 3A, RANKL induced formation of osteoclasts in control cells. In contrast, differentiation into osteoclasts was significantly reduced in the presence of cardamonin. Moreover, the osteoclasts formation was decreased with increasing concentration of cardamonin (Fig. 3A and 3B). As little as 100 nM cardamonin had a significant effect on RANKL-induced osteoclast formation. Under these conditions, the viability of cells was not significantly affected (Fig. 3C).

We next examined whether cardamonin affects RANKL-induced bone resorption by measuring pit formation of RAW 264.7 cells. Results indicated that RANKL induced the pit formation, whereas cardamonin inhibited the pit formation (Fig. 3D). These results suggest that cardamonin can suppress bone resorption.

To determine whether cardamonin inhibits osteoclastogenesis in a time-dependent manner, RAW 264.7 cells were incubated with cardamonin for 3, 4, or 5 days and allowed to differentiate into osteoclasts by RANKL. Morphological observations clearly demonstrated that RAW 264.7 cells differentiated into osteoclasts after RANKL addition, and that cardamonin inhibited this differentiation (Fig. 4A). The extent of suppression was measured by counting the number of TRAP-positive osteoclasts per well (Fig. 4B). We observed that RANKL induced osteoclast differentiation in a time-dependent manner, with a maximum of TRAP-positive osteoclasts per well at day 5 (Fig. 4A and 4B). On the other hand, cardamonin decreased the number of TRAP-positive osteoclasts in a dose-dependent manner, with a strong inhibition at 500 nM at all days examined (Fig. 4B).
Whether cardamonin can suppress RANKL-induced osteoclastogenesis markers was investigated. Osteoclast precursor RAW 264.7 cells were treated with or without cardamonin in the presence of RANKL for 0, 1, 2, and 3 days. As shown in Figure 4C, RANKL up-regulated the expression of NFATc1, c-
Src and MMP-9, whereas cardamonin significantly suppressed the expression of these osteoclastogenesis markers.

Cardamonin acts at an early step in the pathway leading to RANKL-induced osteoclastogenesis

It generally takes as long as 5 days for RAW 264.7 cells to differentiate into osteoclasts in presence of RANKL. To elucidate at what point in this pathway cardamonin acts, cells were treated initially with RANKL, cardamonin was added 1, 2, 3, and 4 days after RANKL addition, and then its effect on formation of osteoclast was measured (Fig. 5A). As determined by observation (Fig. 5A, right panel) and by counting of TRAP-positive osteoclasts per well (Fig. 5B), cardamonin markedly inhibited osteoclast formation when the cells were exposed to the compound for 1 or 2 days.

Figure 2. Cardamonin suppresses RANKL-induced IκBα degradation and phosphorylation through inhibition of IKK activity. (A) RAW 264.7 cells (1.5 × 10⁶/well) were incubated with 20 μM of cardamonin for 12 h and then treated with 10 nM RANKL for the indicated times (min). Cytoplasmic extracts were examined for IκBα degradation by western blot using an anti-IκBα antibody. Anti-β-actin was used as a loading control. (B) RAW 264.7 cells (1.5 × 10⁶/well) were pretreated with cardamonin (20 μM) for 12 h, then incubated with ALLN (50 μg/mL) for 30 min, and then treated with RANKL (10 nM) for 15 min. Cytoplasmic extracts were prepared and analyzed by western blot using phospho-IκBα antibody. The same membrane was reprobed with IκBα and β-actin antibody. (C) RAW 264.7 cells were pretreated with cardamonin (20 μM) for 12 h and then incubated with RANKL (10 nM) for the indicated times (min). Whole-cell extracts were immunoprecipitated using an antibody against IKKα and analyzed by an immune complex kinase assay using recombinant GST-IκBα as described in Materials and Methods. To examine the effect of cardamonin on the level of IKK proteins, whole-cell extracts were analyzed by western blot using anti-IKKα and anti-IKKβ antibodies. Values below the blot indicate fold change (GST-IκBα/IKKα) compared with control. Control was set as fold 1. (D) RAW 264.7 cells (1.5 × 10⁶/well) were pre-incubated with cardamonin for 12 h and then exposed to RANKL (10 nM) for the indicated times. Whole-cell extracts were analyzed by western blotting using relevant antibodies.
days after RANKL stimulation. By days 3 and 4 after RANKL addition, however, osteoclast formation was no longer completely prevented by cardamonin (Fig. 5A and 5B), indicating that cardamonin probably acts at an early step in the osteoclast differentiation pathway.

Cardamonin inhibits osteoclastogenesis induced by tumor cells

Breast cancer [18] and multiple myeloma cells [19] are commonly linked with osteoclastogenesis. Whether cardamonin modulates osteoclastogenesis of RAW 264.7 cells induced by tumor cells was examined. Results indicated while both MDA-MB-231 breast cancer cells and U266 multiple myeloma cells induced RAW 264.7 cells to differentiate into osteoclasts, cardamonin suppressed the osteoclast formation (Fig. 6A and 6B). These results indicate that cardamonin suppresses the osteoclastogenesis induced by tumor cells.

Cardamonin suppresses RANKL expression in U266 cells

Because U266 cells induced osteoclastogenesis of RAW264.7 cells, whether U266 cells express RANKL was investigated. For this, the whole cell protein extract prepared from control and
treated U266 cells were examined for RANKL expression. We found that U266 cells express RANKL and cardamonin suppressed the expression in a dose-dependent manner (Fig. 6C).

Inhibition of NF-κB abrogates osteoclastogenesis

Whether osteoclastogenesis induced by RANKL is due to activation of NF-κB by the cytokine, was also investigated using NF-κB specific inhibitor. NF-κB essential modulator (NEMO) binding peptide (NBP) is a peptide that binds to NEMO and thus blocks its activity to activate NF-κB. Our results in Figures 7A and 7B showed that RANKL induced osteoclastogenesis and NBP inhibited the differentiation. As shown in Fig. 7C, this peptide also blocked the RANKL-induced NF-κB activation.

Discussion

Osteoclasts, which are responsible for bone resorption, are rare; each 1 mm³ of bone contains only two or three osteoclasts. Despite these small numbers, loss of function of osteoclasts or decrease in their number leads to osteosclerosis/osteopetrosis. On the other hand, an increase in their number or function induces bone osteoporosis, indicating that osteoclasts play a pivotal role in bone loss [20,21]. Systemic hormones and cytokines provide the molecular cues that control osteoclastogenesis and thus maintain homeostasis [1]. RANKL has emerged as a major mediator of osteoclastogenesis. Major problems associated with aging and age-associated diseases such as arthritis, cancer, and other chronic inflammatory illnesses are disturbance of this balance. Thus safe,
efficacious, and affordable compounds that can inhibit bone loss are needed. Cardamonin is one such compound that has been shown to suppress inflammatory pathways. The goal of this study was to investigate the effect of cardamonin, a bioactive chalcone, on RANKL-induced NF-κB activation and on osteoclastogenesis induced by both RANKL and tumor cells.

A number of inflammatory cytokines produced during different types of inflammation have a synergic role in osteoclastogenesis,
include interleukins 1 and 6, TNF-α, and oncostatin M. These have been reported to stimulate osteoclastic differentiation and bone resorption [22,23,24]. Chemokines are chemotactic signals for monocytes that can facilitate the fusion of monocytes into multinucleated osteoclasts [25]. Our results indicate that RANKL activates NF-κB in osteoclast precursor cells through activation of IKK and subsequent IκBα phosphorylation and degradation. The RANKL-induced NF-κB activation signaling pathway differs from the TNF-induced pathway. For instance, NIK, which may function as an activator of IKKα, is necessary in RANKL-induced NF-κB activation [14]; however, it is dispensable for TNF-induced NF-κB activation [26]. Thus NIK-deficient osteoclast precursors include interleukins 1 and 6, TNF-α, and oncostatin M. These have been reported to stimulate osteoclastic differentiation and bone resorption [22,23,24]. Chemokines are chemotactic signals for monocytes that can facilitate the fusion of monocytes into multinucleated osteoclasts [25]. Our results indicate that RANKL activates NF-κB in osteoclast precursor cells through activation of IKK and subsequent IκBα phosphorylation and degradation. The RANKL-induced NF-κB activation signaling pathway differs from the TNF-induced pathway. For instance, NIK, which may function as an activator of IKKα, is necessary in RANKL-induced NF-κB activation [14]; however, it is dispensable for TNF-induced NF-κB activation [26]. Thus NIK-deficient osteoclast precursors
have been reported to not respond to RANKL in an in vitro differentiation system devoid of osteoblasts [27]. We found that cardamonin inhibited RANKL-induced IKK activation, leading to suppression of NF-κB activation. That cardamonin inhibits RANKL-induced ERK1/2 and p38 activation indicates the multitargeting activities of cardamonin.

Other studies have shown that IKKβ, but not IKKα, is a potent regulator of inflammation-induced bone loss and is required for osteoclastogenesis and inflammatory arthritis [28]. The study reported here is the first showing that cardamonin can suppress RANKL-induced IKK activation and consequently NF-κB activation. How cardamonin inhibits RANKL-induced IKK activation is not clear.

By recruiting the adapter proteins TRAF 2, 3, 5, and 6 and NIK, RANK activates NF-κB and the JNK, p38 MAPK, and p44/p42 MAPK signaling pathways [5,13]. In addition to its role in inflammatory diseases, the NF-κB signaling pathway has been demonstrated to be a major mediator of bone loss [29]. It is already proven that NF-κB p50 and p52 expression are essential for the differentiation of RANK-expressing osteoclast precursors into TRAP-positive osteoclasts in response to RANKL and other osteoclastogenic cytokines [30].

RANKL has been shown to play a major role in cancer-associated osteoclast differentiation. Furthermore, a series of electrolytes and degradative enzymes have been implicated in osteoclastogenesis, bone resorption, and calcium homeostasis [4,31]. Mice deficient in the rankl gene have been shown to display severe osteopetrosis, stunted growth, defective tooth eruption, and osteoblasts that cannot support osteoclastogenesis [31]. Thus agents that can inhibit RANKL signaling have a great potential for inhibiting osteoclastogenesis.

Our results indicate that cardamonin effectively inhibits RANKL-induced osteoclastogenesis. A kinetic study indicated that cardamonin acts at an early step in the osteoclast differentiation process. To further confirm that inhibition of the NF-κB signaling pathway is responsible for arrest of the osteoclastogenesis process, we used a cell-permeable peptide that targets the NEMO-binding domain of the IKKα and IKKβ kinases and so prevents NF-κB activation. This NEMO-binding domain peptide has been shown to inhibit osteoclastogenesis in vivo, and also delayed the onset, lowered the incidence, and decreased the severity of rheumatoid arthritis [28]. Moreover, previous studies demonstrated that pharmacological or genetic inactivation of IKKα and/or IKKβ is sufficient for inhibition of osteoclastogenesis and prevention of inflammation and osteolytic bone loss [32,33]. Our results show that the NF-κB inhibitor NEMO-binding domain peptide completely blocked RANKL-induced osteoclastogenesis in the same manner as cardamonin. Interestingly, the inhibitory effect of 100 μM of this peptide was as potent as 500 nM cardamonin, which suggests that cardamonin is 200 times more potent, at least in vitro. These findings indicate that cardamonin’s inhibitory effect on osteoclastogenesis is probably specific to NF-κB inhibition. We found that the targets downstream to NF-κB activation pathway and known markers of osteoclastogenesis such as NFATc and MMP-9 were also suppressed by cardamonin treatment. It is likely that the reduction in NFATc and MMP-9 expression due to NF-κB inhibitory effects of cardamonin contribute to its anti-osteoclastogenic activities.

A major health problem today that affects over 350,000 patients in the United States annually is malignant tumors of skeleton as the primary site as well as metastatic bone lesions. Among them, 70% to 95% of multiple myeloma patients and up to 75% of patients with advanced breast cancer or prostate cancer develop bone metastasis. A major complication in metastatic breast cancer and multiple myeloma is osteoclast-mediated bone destruction [7,34]. Breast cancers commonly cause osteolytic metastasis that depends on osteoclast-mediated bone resorption [35], but the mechanism responsible for this has not yet been clarified. We showed in this study that osteoclastogenesis induced by breast cancer cells is inhibited by cardamonin. Bone resorption is also associated with multiple myeloma [35], and we found that multiple myeloma cell-induced osteoclastogenesis was also suppressed by cardamonin. As IKK activation is known to accelerate the proliferation and metastasis of cancer cells [36,37], its inhibitors, such as cardamonin, might have potential in the treatment of cancers that metastasize to the bone. These tumors have been shown to express RANKL [19,38] and exhibit constitutive NF-κB activation [39,40]. Thus, it can be concluded that these tumors activate osteoclastogenesis through RANKL expression.

The bisphosphonates are the only drugs now available for treatment of bone metastasis or cancer-related bone diseases. These drugs are highly toxic, however, and adverse effects such as renal impairment or osteonecrosis of the jaw have been reported [41]. An antibody to RANKL, denosumab (Prolia), has been approved recently for treatment of osteoporosis [42]. Cardamonin is derived from the seed of grass cardamom (A. katsumadai Hayata) and the fruit of black cardamom (A. subulatum), and should have minimum toxicity, as it is used routinely for traditional medicine [43,44]. Thus cardamonin could be used in the treatment of secondary bone lesions associated with cancer and also nonmalignant diseases such as postmenopausal osteoporosis, Paget disease, and rheumatoid arthritis. Further studies are needed, however, to confirm whether cardamonin can suppress osteoclastogenesis in vivo.

**Acknowledgments**

We thank Kathryn Hale for editorial review of this manuscript. Dr. Aggarwal is the Ransom Horne, Jr., Professor of Cancer Research.

**Author Contributions**

Conceived and designed the experiments: BS SP VRY BBA. Performed the experiments: BS SP VRY SR. Analyzed the data: SCG BBA. Contributed reagents/materials/analysis tools: NY AM. Wrote the paper: BS SCG BBA.
References

1. Yavropoulou MP, Yovos JG (2008) Osteoclastogenesis—current knowledge and future perspectives. J Musculoskelet Neuronal Interact 8: 204–216.

2. Anderson DM, Maraskovsky E, Billingsley VL, Dougall WC, Tometsko ME, et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell function and dendritic-cell function. Nature 390: 175–179.

3. Jin W, Chang M, Paul EM, Babu G, Lee AF, et al. (2008) Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Investig 118: 1850–1866.

4. Lacy DL, Timms E, Tan HL, Kelly M, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–176.

5. Darras BG, Harada V, NiJ, Moore PA, Aggarwal BB (1998) Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem 273: 20351–20355.

6. Takafuji Y, Kim S, Koga T, Kim Y (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) in osteoclasts in terminal differentiation of osteoclasts, Dev Cell 3: 899–901.

7. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and therapy. Cancer Res 61: 163–176.

8. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243s–6249s.

9. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT (2010) Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7: 641–651.

10. Sturge J, Caley MP, Waxman J (2011) Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 8: 357–368.

11. Chow YL, Lee KH, Vidyasaran S, Lajoie NH, Akhtar MN, et al. (2012) Cardamonin inhibits NF-kappaB activation. Cancer Res 72: 2359–2369.

12. Takahashi A, Yamamoto N, Murakami A (2011) Cardamonin suppresses nitric oxide production via blocking the IFN-gamma/STAT pathway in endotoxin-challenged peritoneal macrophages of ICR mice. Life Sci 89: 337–342.

13. Reuter S, Prasad S, Phromnoi K, Kannappan R, Yadav VR, et al. (2010) NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 15: 1200–1210.

14. Wei S, Teitelbaum SL, Wang MW, Ross FP (2001) Receptor activator of NF-kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 22: 389–417.

15. Zou W, Bar-Shavit Z (2002) Dual modulation of osteoclast differentiation by lipopolysaccharide. J Bone Miner Res 17: 1211–1218.

16. Kim MS, Magno CL, Day CJ, Morrison NA (2006) Induction of chemokines and chemokine receptors CCR2b and CCR4 in authentic human osteoclasts differentiated with RANKL and osteoclast-like cells differentiated by MCP-1 and RANTES. J Cell Biochem 97: 512–518.

17. Uldrik M, Good L, Xiao G, Hachaj EW, Zandi E, et al. (1998) NF-kappaB-inducing kinase and I kappaB kinase participate in human T-cell leukemia virus I Tax-mediated NF-kappaB activation. J Biol Chem 273: 21132–21136.

18. Novack DV, Yin L, Hagen-Stapleton A, Schreiber RD, Goeddel DV, et al. (2003) The I kappab B function of NF-kappaB-R2 p100 controls stimulated osteoclastogenesis. J Exp Med 196: 771–781.

19. Dai S, Hirayama T, Abbas S, Abum-Amer Y (2004) The I kappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 279: 37219–37222.

20. Xu J, Wu HF, Ang ES, Yip K, Woloszyzn M, et al. (2009) NF-kappaB-modulators in osteolytic bone diseases. Cytokine Growth Factor Rev 20: 7–17.

21. Xing L, Bushnell TP, Carlson L, Tai Z, Tondevold E, et al. (2002) NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 17: 1200–1210.

22. Carlin BI, Andriele GL (2000) The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 86: 2989–2994.

23. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584–593.

24. Jourdan M, Moreaux J, Vos JD, Hose D, Mahtouk K, et al. (2007) Targeting the NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol 138: 160–168.

25. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, et al. (1990) IL-6 is produced by osteoclasts and induces bone resorption. J Biol Chem 265: 2989–2994.

26. Chaisson ML, Braashteter DG, Derry JM, Armstrong AP, Tometsko ME, et al. (2004) Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 279: 54841–54848.

27. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, et al. (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of PARP inhibitors in the management of BRCA1 or BRCA2 mutation carriers with advanced breast cancer. J Clin Oncol 25: 2993–2999.

28. Takeda Y, Yamamoto N, Murakami A, et al. (2011) Cardamonin suppresses nitric oxide production via blocking the IFN-gamma/STAT pathway in endotoxin-challenged peritoneal macrophages of ICR mice. Life Sci 89: 337–342.

29. Aihara T, Hanyama T, Yasui M, et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell function and dendritic-cell function. Nature 390: 175–179.

30. Biwata DK, Shi Q, Saily S, Streckl I, Ghosh S, et al. (2006) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25: 10137–10142.

31. Yavropoulou MP, Yovos JG (2008) Osteoclastogenesis—current knowledge and future perspectives. J Musculoskelet Neuronal Interact 8: 204–216.

32. Reuter S, Prasad S, Phromnoi K, Kannappan R, Yadav VR, et al. (2010) Cardamonin suppresses osteoclastogenesis induced by receptor activator of NF-kappaB ligand and tumor cells in vitro through inhibition of the NF-kappaB cell signaling pathway. Mol Cancer Res 8: 1425–1436.

33. Koyama H, Miyazaki T, Ikeda K, Amemiya S, Iwagawa N, et al. (2005) Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through the suppression of TAK-1 and receptor-interacting protein-activated I kappaB alpha kinase. Mol Pharmacol 71: 1703–1714.

34. Keen RJ, Yeo GC, Somerfield MR,Flyna PJ, Halabi S, et al. (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of PARP inhibitors in the management of BRCA1 or BRCA2 mutation carriers with advanced breast cancer. J Clin Oncol 25: 2993–2999.

35. Koyama H, Miyazaki T, Ikeda K, Amemiya S, Iwagawa N, et al. (2005) Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through the suppression of TAK-1 and receptor-interacting protein-activated I kappaB alpha kinase. Mol Pharmacol 71: 1703–1714.

36. Keen RJ, Yeo GC, Somerfield MR, Flyna PJ, Halabi S, et al. (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25: 10137–10142.

37. Koyama H, Miyazaki T, Ikeda K, Amemiya S, Iwagawa N, et al. (2005) Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through the suppression of TAK-1 and receptor-interacting protein-activated I kappaB alpha kinase. Mol Pharmacol 71: 1703–1714.